ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Trihexyphenidyl: Drug information

Trihexyphenidyl: Drug information
(For additional information see "Trihexyphenidyl: Patient drug information" and see "Trihexyphenidyl: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Anti-Parkinson Agent, Anticholinergic;
  • Anticholinergic Agent
Dosing: Adult
Extrapyramidal symptoms, medication-induced

Extrapyramidal symptoms (eg, dystonia and parkinsonism), medication-induced (treatment):

Note: Anticholinergic agents are not recommended for the treatment of akathisia or tardive dyskinesia (Ref). Duration of therapy is based on the severity of EPS reaction, pharmacologic profile of the causative agent (eg, half-life, adverse effects), and patient risk factors (Ref). Some experts recommend attempting taper and discontinuation after several weeks to months (Ref).

Oral: Initial: 1 mg/day; increase as necessary to usual range: 5 to 15 mg/day in 3 to 4 divided doses.

Parkinsonism

Parkinsonism: Oral: Initial: 1 mg/day, increase by 2 mg increments at intervals of 3 to 5 days; usual dose: 6 to 10 mg/day in 3 to 4 divided doses; doses of 12 to 15 mg/day may be required. Consider dosage reduction when used concomitantly with levodopa, the usual dose of each may need to be reduced. Usual range: 3 to 6 mg/day in divided doses.

Discontinuation of therapy: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome, exacerbation of parkinsonism, and withdrawal symptoms (eg, palpitations, headache, insomnia, fainting, and nausea (Ref)). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.

Dosing: Older Adult

Avoid use (Ref).

Dosing: Pediatric

(For additional information see "Trihexyphenidyl: Pediatric drug information")

Dystonia in cerebral palsy

Dystonia in cerebral palsy: Limited data available: Children and Adolescents: Oral: Initial: 0.1 to 0.2 mg/kg/day in 2 to 3 divided doses; after the first week, titrate weekly or every 2 weeks as tolerated (eg, increase by 0.15 mg/kg/day or increase by 10% to 20%) (Ref). Usual maximum daily dose: 0.75 mg/kg/day in 3 divided doses (Ref). Doses as high as 2.6 mg/kg/day in 3 divided doses have been described (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Gastrointestinal: Nausea (30% to 50%), xerostomia (30% to 50%)

Nervous system: Dizziness (30% to 50%), nervousness (30% to 50%)

Ophthalmic: Blurred vision (30% to 50%)

Postmarketing:

Cardiovascular: Paradoxical bradycardia (sinus bradycardia) (Blumensohn 1986), tachycardia

Dermatologic: Erythema of skin (Zhao 2022), hypohidrosis (Zhao 2022), skin rash, xeroderma

Endocrine & metabolic: SIADH (Zhao 2022)

Gastrointestinal: Constipation (Zhao 2022), paralytic ileus, toxic megacolon, vomiting (Zhao 2022)

Genitourinary: Urinary hesitancy, urinary retention (Zhao 2022)

Nervous system: Anxiety (Zhao 2022), asthenia, choreiform movements (Warne 1979, cognitive dysfunction (including confusion and memory impairment) (Zhao 2022), delusion, drowsiness, euphoria (Jellinek 1977), hallucination (Zhao 2022), headache, myasthenia gravis (Ueno 1987), neuroleptic malignant syndrome (with abrupt withdrawal), paranoid ideation

Neuromuscular & skeletal: Dyskinesia (including tardive dyskinesia [orobuccal] (Hauser 1993, Zhao 2022)

Ophthalmic: Angle-closure glaucoma (including blindness), cycloplegia, increased intraocular pressure, mydriasis

Miscellaneous: High fever (Zhao 2022), malignant hyperthermia (Zhao 2022)

Contraindications

Hypersensitivity to trihexyphenidyl or any component of the formulation; narrow angle glaucoma.

Warnings/Precautions

Concerns related to adverse effects:

• Anhidrosis/hyperthermia: May cause anhidrosis and hyperthermia. Severe anhidrosis and fatal hyperthermia have occurred; use with caution in hot weather or during exercise, especially when administered concomitantly with other anticholinergic drugs to chronically ill patients, patients with alcohol use disorder, patients with CNS disease, or persons doing manual labor in a hot environment.

• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); monitor patients requiring long-term use.

• CNS depression: May impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).

• Ocular effects: May precipitate angle closure with an increase in intraocular pressure. If blurring of vision occurs, consider the possibility of narrow angle glaucoma; blindness because of aggravation of narrow angle glaucoma has been reported.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension.

• GI obstruction: Use with caution in patients with obstructive disease of the GI tract.

• Glaucoma: Use with caution in patients with glaucoma; blindness after long-term use due to narrow angle glaucoma has been reported.

• Hepatic impairment: Use with caution in patients with hepatic impairment.

• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture or retention.

• Psychiatric effects: May impair memory and further exacerbate cognitive deficits in elderly patients; in high doses may cause confusion, delirium, and hallucinations (Holloman 1997; Tonda 1994).

• Renal impairment: Use with caution in patients with renal impairment.

• Tardive dyskinesia: Not recommended for use in patients with tardive dyskinesia unless concomitant Parkinson disease or tardive dystonia exists (Kang 1986); trihexyphenidyl does not relieve symptoms of tardive dyskinesia and may potentially exacerbate symptoms.

Other warnings/precautions:

• Discontinuation of therapy: Dose reduction or discontinuation of trihexyphenidyl has been associated with neuroleptic malignant syndrome (NMS), exacerbation of Parkinsonism, and withdrawal symptoms including tension, irritability, perspiration, palpitations, headache, insomnia, abdominal distress, anorexia, faint or choking feelings, nausea, and photophobia (McInnis 1985). According to the manufacturer's labeling, withdraw trihexyphenidyl gradually; abrupt or rapid discontinuation may result in acute exacerbation of symptoms or side effects (Manos 1981a; Manos 1981b).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral:

Generic: 0.4 mg/mL (473 mL)

Tablet, Oral, as hydrochloride:

Generic: 2 mg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Trihexyphenidyl HCl Oral)

0.4 mg/mL (per mL): $0.11

Tablets (Trihexyphenidyl HCl Oral)

2 mg (per each): $0.18 - $0.55

5 mg (per each): $0.36 - $1.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as hydrochloride:

Generic: 2 mg, 5 mg

Administration: Adult

Oral: May be administered before or after meals (if excessive dry mouth develops, consider administering before meals unless it causes nausea; postencephalitic patients who are prone to excessive salivation may prefer to take after meals); tolerated best if given in 3 daily doses and with food. High doses (>10 mg/day) may be divided into 4 doses (at each meal and at bedtime).

Administration: Pediatric

Oral: May be taken before or after meals (if excessive dry mouth develops, consider administering before meals unless it causes nausea); tolerated best if administered in 3 daily doses and with food. High doses (>10 mg/day) may be divided into 4 doses, at meal times and at bedtime.

Use: Labeled Indications

Extrapyramidal symptoms, medication-induced (treatment): Management of medication-induced extrapyramidal symptoms.

Parkinsonism: Adjunctive therapy in the treatment of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic).

Medication Safety Issues
Sound-alike/look-alike issues:

Trihexyphenidyl may be confused with trifluoperazine

Older adult: High-Risk Medication:

Beers Criteria: Trihexyphenidyl is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to its highly anticholinergic properties. It is not recommended for the prevention or treatment of extrapyramidal symptoms with antipsychotics. In the treatment of Parkinson disease, more effective agents are available (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy

Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. Risk C: Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Risk X: Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination

Lisuride: Trihexyphenidyl may enhance the adverse/toxic effect of Lisuride. Risk X: Avoid combination

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy

Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. Risk C: Monitor therapy

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid combination

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid combination

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination

Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider therapy modification

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Pregnancy Considerations

Animal reproduction studies have not been conducted. One case report did not show evidence of adverse events after trihexyphenidyl administration during pregnancy (Robottom 2011).

Breastfeeding Considerations

It is not known if trihexyphenidyl is present in breast milk. The manufacturer recommends that caution be exercised when administering trihexyphenidyl to patients who are breastfeeding. Anticholinergic agents may suppress lactation.

Dietary Considerations

May be taken before or after meals; tolerated best if given with food.

Monitoring Parameters

Gonioscopic evaluations (prior to therapy initiation); IOP (periodically); anticholinergic adverse reactions for patients on long-term therapy (as clinically indicated).

Mechanism of Action

Exerts a direct inhibitory effect on the parasympathetic nervous system. It also has a relaxing effect on smooth musculature; exerted both directly on the muscle itself and indirectly through parasympathetic nervous system (inhibitory effect)

Pharmacokinetics (Adult Data Unless Noted)

Metabolism: Hydroxylation of the alicyclic groups (Brocks 1999)

Half-life elimination: 33 hours (Brocks 1999)

Time to peak, serum: 1.3 hours (Brocks 1999)

Excretion: Urine and bile (Brocks 1999)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apo-trihex | Artane | Trihexyphenidyl;
  • (AR) Argentina: Artane | Trihexifenidilo;
  • (AT) Austria: Artane;
  • (AU) Australia: Artane;
  • (BD) Bangladesh: Delpark | Heximax | Hexinor | Hexiphen | Parkifen | Parkitrol | Perkinor | Tridyl | Trihexy;
  • (BE) Belgium: Artane;
  • (BG) Bulgaria: Parcisol | Parkisan;
  • (BR) Brazil: Artane | Triexidyl;
  • (CH) Switzerland: Artane;
  • (CL) Chile: Artane | Tenvatil | Tonaril;
  • (CN) China: An tan | Artane | Benzhexol | Benzhexol hydrochloride | Trihexyphenidyl;
  • (CO) Colombia: Artane | Trihexifenidilo;
  • (CZ) Czech Republic: Artane;
  • (DE) Germany: Artane | Parkopan;
  • (DO) Dominican Republic: Artane | Tremol | Tremolin;
  • (EE) Estonia: Cyclodol | Parkopan;
  • (EG) Egypt: Parkinol;
  • (ES) Spain: Artane;
  • (FI) Finland: Artane;
  • (FR) France: Artane | Trihexyphenidyl richard;
  • (GB) United Kingdom: Agitane | Artane | Bentex | Benzhexol | Benzhexol dc | Broflex | Broflex bms | Trihexyphenidy | Trihexyphenidyl;
  • (GR) Greece: Artane | Benzhexol;
  • (HK) Hong Kong: Adtendyl | Apo-trihex | Artandyl | Artane | Benzhexol;
  • (ID) Indonesia: Arkicel | Arkine | Artane | Hexymer | Parkinal | Trihexyphenidyl;
  • (IE) Ireland: Artane | Broflex;
  • (IL) Israel: Artane | Partane | Rodenal;
  • (IN) India: Antichol | Barohexy | Benz | Bexol | Dyskinil | Dystonil | Ecitane | Emelaxy | Epsinil | Hex | Hexylent | Lahexy | Manohexy | Maphyl | Matcalm | Pacitane | Parkin | Parkinta | Parkitane | Parnil | Parnon | Relihexy | Tanzee | Thp | Tri ex | Triden | Trihexy | Trikotame | Triphen | Trit 2 | Tryal | Xydyl;
  • (IQ) Iraq: Samhexol;
  • (IT) Italy: Artane;
  • (JO) Jordan: Artane | Parkizole;
  • (JP) Japan: Artane | Parkines towa | Parkiness merck hoei | Parkisonal | Pyramistin | Sedrena | Stobrun | Topcron | Tremin | Trihexin | Trihexyphenidyl Hcl Nipro | Triphedinon;
  • (KE) Kenya: Benzhexol | Parkin;
  • (KR) Korea, Republic of: Artane | Trihexin | Trihexyne | Trihexyphenidyl hydrochlorid;
  • (KW) Kuwait: Artane;
  • (LB) Lebanon: Artane | Benzhexol;
  • (LT) Lithuania: Cyclodol | Parkisan | Parkopan | Triphen | Triphenidyl;
  • (LU) Luxembourg: Artane;
  • (LV) Latvia: Artane | Cyclodol | Parkisan | Parkopan | Triphenidyl;
  • (MA) Morocco: Artane;
  • (MX) Mexico: Artane | Hipokinon | Trihexifenidilo;
  • (MY) Malaysia: Aca | Apo-trihex | B-Hex | Benzhexol | Pharmaniaga benzhexol | Uphazhexol;
  • (NG) Nigeria: Axzol | Babazole | Benzhexol | Cinnamon benzhexol | Embazol | Oxazol | Pbenz | Royale benzhexol;
  • (NL) Netherlands: Artane;
  • (NO) Norway: Artane | Trihexyphenidyl;
  • (NZ) New Zealand: Artane;
  • (PE) Peru: Artane;
  • (PH) Philippines: Artane;
  • (PK) Pakistan: Hexidyl | Pacitane;
  • (PL) Poland: Artane | Parkopan | Triphenidyl;
  • (PR) Puerto Rico: Artane | Trihexyphenidyl;
  • (PT) Portugal: Artane;
  • (PY) Paraguay: Desagit;
  • (RU) Russian Federation: Cyclodol | Parkopan | Romparkin | Trihexyphenidyl | Trihexyphenidyl ferein | Trihexyphenidyl organica | Trihexyphenidyl ph | Trihexyphenidyl pharmstandart | Triphen;
  • (SA) Saudi Arabia: Artane;
  • (SE) Sweden: Artane | Pargitan;
  • (SG) Singapore: Apo-trihex | Artyl | B-Hex | Beahexol | Benzhexol;
  • (SI) Slovenia: Artane;
  • (TH) Thailand: Aca | Acamed | Artane | Benzhexol | Pozhexol | Tridyl;
  • (TN) Tunisia: Apo-trihex | Artane | Parkizol;
  • (TW) Taiwan: Artane | Artine | Atan | B.h.l | Benzhexol | Benzox | Parkindyl | Partane | Switane;
  • (UA) Ukraine: Cyclodol | Parcopan | Parkopan | Trifen;
  • (UG) Uganda: Benzhexol;
  • (UY) Uruguay: Artane;
  • (ZA) South Africa: Artane | Benzhexol;
  • (ZM) Zambia: Benzhexol;
  • (ZW) Zimbabwe: Apo-trihex
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Ben-Pazi H. Trihexyphenidyl improves motor function in children with dystonic cerebral palsy: a retrospective analysis. J Child Neurol. 2011;26(7):810-816. [PubMed 21498790]
  3. Blumensohn R, Razoni G, Shalev A, Munitz H. Bradycardia due to trihexyphenidyl hydrochloride. Drug Intell Clin Pharm. 1986;20(10):786-787. doi:10.1177/106002808602001012 [PubMed 3769769]
  4. Brocks DR, “Anticholinergic Drugs Used in Parkinson's Disease: An Overlooked Class of Drugs From a Pharmacokinetic Perspective,” J Pharm Pharmaceut Sci, 1999, 2(2):39-46. [PubMed 10952768]
  5. Carranza-del Rio J, Clegg NJ, Moore A, Delgado MR. Use of trihexyphenidyl in children with cerebral palsy. Pediatr Neurol. 2011;44(3):202-206. [PubMed 21310336]
  6. Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol. 2012;26(9):1167-1174. doi:10.1177/0269881112447988 [PubMed 22651987]
  7. Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. Mov Disord. 1993;8(4):512-514. doi:10.1002/mds.870080417 [PubMed 8232363]
  8. Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997:54(1):2461-2477. [PubMed 9359953]
  9. Jellinek T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Syst. 1977;38(5):353-355. [PubMed 852367]
  10. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord. 1986;1(3):193-208. doi: 10.1002/mds.870010305. [PubMed 2904118]
  11. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]
  12. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103. doi: 10.1093/schbul/sbp130. [PubMed 19955388]
  13. Manos N, Gkiouzepas J, Logothetis J. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry. 1981a;138(2):184-188. [PubMed 6109453]
  14. Manos N, Gkiouzepas J, Tzotzoras T, Tzanetoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt? J Nerv Ment Dis. 1981b;169(10):659-661. [PubMed 6116743]
  15. McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand. 1985;71(3):297-303. [PubMed 3984771]
  16. Rice J and Waugh MC, "Pilot Study on Trihexyphenidyl in the Treatment of Dystonia in Children With Cerebral Palsy," Child Neurol, 2009, 24(2):176-82. [PubMed 19182155]
  17. Robottom BJ and Reich SG, "Exposure to High Dosage Trihexyphenidyl During Pregnancy for Treatment of Generalized Dystonia: Case Report and Literature Review," Neurologist, 2011, 17(6):340-1. [PubMed 22045287]
  18. Sanger TD, Bastian A, Brunstrom J, et al, "Prospective Open-Label Clinical Trial of Trihexyphenidyl in Children With Secondary Dystonia Due to Cerebral Palsy," J Child Neurol, 2007, 22(5):530-7. [PubMed 17690057]
  19. Trihexyphenidyl hydrochloride tablets [prescribing information]. Buffalo Grove, IL: Pack Pharmaceuticals; June 2015.
  20. Trihexyphenidyl hydrochloride oral solution [prescribing information]. Greenville, SC: Pai Pharmaceutical Associates; October 2010.
  21. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy. 1994;14(5):543-560. [PubMed 7997388]
  22. Ueno S, Takahashi M, Kajiyama K, et al. Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission. Neurology. 1987;37(5):832-833. doi:10.1212/wnl.37.5.832 [PubMed 3033545]
  23. Warne RW, Gubbay SS. Choreiform movements induced by anticholinergic therapy. Med J Aust. 1979;1(10):465. [PubMed 470689]
  24. Zhao J, Xu G, Feng C, et al. Trihexyphenidyl induced malignant hyperthermia in a patient with Parkinson's disease complicated with pneumonia: a case report. Medicine (Baltimore). 2020;99(20):e20129. doi:10.1097/MD.0000000000020129 [PubMed 32443324]
Topic 10022 Version 283.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟